United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics (UTHR) has 6 years of Short term Debt data on file, last reported at $200.0 million in Q1 2025.

• For the quarter ending Q1 2025, Short term Debt fell 50.0% year-over-year to $200.0 million; the trailing twelve-month figure through Mar 2025 stood at $200.0 million (down 50.0% YoY), and the FY2024 full-year result was $300.0 million, down 25.0% from the prior year.
• Short term Debt declined to $200.0 million in Q1 2025, from $300.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $400.0 million in Q4 2023 to a low of $200.0 million in Q1 2025.
• A 3-year average of $342.9 million and a median of $400.0 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 33.33% in 2024 and slumped 50.0% in 2025, its largest moves.
• Tracing UTHR's Short term Debt over 3 years: stood at $400.0 million in 2023, then dropped by 25.0% to $300.0 million in 2024, then sank by 33.33% to $200.0 million in 2025.
• Business Quant data shows UTHR's Short term Debt at $200.0 million in Q1 2025, $300.0 million in Q4 2024, and $400.0 million in Q3 2024.